The vaccine of the American-German company Pfizer in the elderly and in people with chronic diseases loses efficiency in six months. About this in an interview with RIA Novosti told the head of the therapeutic department of the Israeli Hospital Shamir Asaf Arof, the infectious player Galina Goltzman.
“COVID-19 appeared a year and a half ago, an unknown job, we learn to understand it, gain experience and determine the future strategy, tactics. When the vaccination campaign began, Pfizer said that the vaccination would provide protection against coronavirus to six “For months. We hoped that it would last longer. But it turned out to be a fairly accurate forecast, especially registered risk groups,” said Goltzman.
According to her, the risk of incidence of incidence was recorded among grafts over 65 years old, especially over 80 years old. The doctor suggested that the elderly people and chronic diseases will need a re-vaccination in six months, while people outside the risk groups, it will need to be done in a year.
Goltzman also noted that a certain role in the growth of infection cases also played a new strain “Delta”, against which, according to her, the effectiveness of the vaccine is lower than against the “British” strain.
Earlier, director of the National Research Center of Epidemiology and Microbiology. N.F. Gamalei Academician RAS Alexander Ginzburg spoke about the effectiveness of the “satellite V”. August 11 marks the year from the date of its registration and, according to Ginzburg, “satellite V” for the year of use confirmed its effectiveness and quality.